Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

• Published in: Current hematologic malignancy reports 2017-12, Vol.12 (6), p.537-546
• Main Authors: Ragon, Brittany Knick, DiNardo, Courtney D.
• Format: Article
• Language: English
• Subjects: Acute Myeloid Leukemias (H Erba; Geriatrics/Gerontology; Hematology; Medicine; Medicine & Public Health; Oncology; Section Editor; Topical Collection on Acute Myeloid Leukemias
• ISSN: 1558-8211; 1558-822X
• DOI: 10.1007/s11899-017-0418-6

Purpose of Review Over the past decade, the pathogenic role of mutations in isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with AML, has been defined, allowing for the development of specific therapeutic strategies for IDH-mutant AML. In this review, the landscape and progress of targeted therapeutics aimed at IDH mutations in AML and related myeloid malignancies will be described. Recent Findings Since 2013, several mutant IDH-targeted inhibitors have been developed, and nearly a dozen clinical trials have opened specifically for IDH-mutant hematologic malignancies. Preliminary results for several of these investigations have shown evidence of safety, tolerability, and encouraging evidence of efficacy. Summary Targeting IDH mutations in AML is a biologically informed and rational strategy to promote clinical responses, primarily through differentiation and maturation of the malignant clone. The use of IDH targeted therapy is expected to soon become part of a genomically defined and individualized AML treatment strategy.